Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Alessandro Vannucchi and Francesco Annunziato.
Alessandro Vannucchi
Connection Strength
0.871
Francesco Annunziato
  1. Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib. Am J Hematol. 2021 11 01; 96(11):E408-E410.
    View in: PubMed
    Score: 0.240
  2. Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS-CoV-2 infection. Immunology. 2020 12; 161(4):345-353.
    View in: PubMed
    Score: 0.227
  3. Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. Leukemia. 2021 04; 35(4):1121-1133.
    View in: PubMed
    Score: 0.225
  4. Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis. Oncotarget. 2017 Nov 14; 8(57):96710-96724.
    View in: PubMed
    Score: 0.179
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.